Fund Holdings — Versant Venture Management, LLC

Total Portfolio Value
$86.75M
Total Bought
$42.16M
Total Sold
$2.07M
Net Transaction
+$40.09M
Filing Period:
Securities
▲▼
SharesValue ($K)
Q3 2024
▲▼
Q4 2024
▲▼
Change
▲▼
Q3 2024
▲▼
Q4 2024
▲▼
Weight (%)
▲▼
Change
▲▼
Monte Rosa Therapeutics, Inc.(GLUE)05,652,922+5,652,922039,23145.22%+39,231
Tempest Therapeutics, Inc.(TPST)03,507,055+3,507,05502,9273.37%+2,927
Adverum Biotechnologies, Inc.506,821506,82103,5582,3672.73%-1,191
Gritstone Oncology, Inc.3,561,1500-3,561,1502,0650—-2,065
Skye Bioscience, Inc.(SKYE)2,007,7042,007,70407,8505,6826.55%-2,168
CRISPR Therapeutics AG(CRSP)498,558498,558023,42219,62322.62%-3,799
Contineum Therapeutics, Inc.(CTNM)918,163918,163017,57413,45115.51%-4,123
Repare Therapeutics, Inc.2,646,6572,646,65709,1053,4674.00%-5,637
Page 1 of 1
Versant Venture Management, LLC — 13F Holdings — Q4 2024 | TickerTrail